Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T in R/R CD19+ NHL
NCT03528421Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- May 2018
- Primary completion
- Apr 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IM19 in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Occurrence of study related adverse events at 2 years. Status: unknown.
02
Drugs
IM19
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03528421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528421.